Table 3. The influencing factors of CD8+T cell, CD8+HLA-DR+T cell, CD8+CD38+T cell and CD4/CD8 dynamics with mixed linear model.
| CD8+ T cell count | CD8+ HLA-DR+T cell% | CD8+CD38+ T cell% | CD4/CD8 | |||||
| Unadjusted Est. Coef (SE)† | Adjusted Est. Coef (SE)† | Unadjusted Est. Coef (SE)† | Adjusted Est. Coef (SE)† | Unadjusted Est. Coef (SE)† | Adjusted Est. Coef (SE)† | Unadjusted Est. Coef (SE)† | Adjusted Est. Coef (SE)† | |
| Age (years) | ||||||||
| 35–49 | −34 (25.9) | −45 (19.6)‡ | 5 (1.1) | 5 (0.9)‡ | −3 (1.2) | −4 (0.8)‡ | 0.01 (0.03) | 0.07 (0.02)‡ |
| >50 | −39 (36.2) | −35 (27.4) | 13 (1.6) | 13 (1.3)‡ | −2 (1.6) | −4 (1.1)‡ | 0.06 (0.04) | 0.10 (0.03)‡ |
| 18–35 | 0 | 0 | ||||||
| Gender | ||||||||
| Female | −82 (35.7) | −17 (26.9) | −6 (1.6) | −5 (1.3)‡ | 0.6 (1.6) | 2 (1.1) | −0.05 (0.04) | −0.016 (0.03) |
| Male | 0 | 0 | 0 | |||||
| CD4 count at baseline(cell/μl) | ||||||||
| 50–100 | 35 (47.9) | −48 (36.2) | −0.3 (2.2) | 3 (1.1) | −3 (2.2) | −2 (1.5) | 0.09 (0.05) | 0.085 (0.04)‡ |
| 100–200 | −64 (38.2) | −162 (29.1)‡ | 4 (1.7) | 7 (1.3) | −6 (1.8) | −6 (1.2)‡ | 0.22 (0.04) | 0.23 (0.03)‡ |
| >200 | 69 (31.1) | −218 (26.0)‡ | 4 (1.4) | 7 (1.8) | −5 (1.4) | −7 (1.1)‡ | 0.44 (0.03) | 0.49 (0.03)‡ |
| <50 | 0 | 0 | 0 | |||||
| Time after ART initiation (years) | ||||||||
| 0.25 | −36 (13.0) | −24 (14.3) | −9 (0.5) | −9 (0.5)‡* | −13 (0.6) | −13 (0.7)‡* | −0.29 (0.01) | 0.17 (0.01)‡* |
| 0.5 | −91 (17.0) | −72 (19.3)‡ | −16 (0.6) | −16 (0.7)‡* | −20 (0.8) | −20 (0.9)‡* | 0.17 (0.01) | 0.22 (0.01)‡* |
| 1 | −111 (19.2) | −88 (22.1)‡ | −19 (0.7) | −19 (0.8)‡ | −25 (0.9) | −25 (1.0)‡* | 0.23 (0.01) | 0.29 (0.01)‡* |
| 2 | −115 (20.8) | −88 (23.7)‡ | −21 (0.8) | −21 (0.9)‡ | −30 (0.9) | −29 (1.1)‡* | 0.31 (0.01) | 0.36 (0.01)‡* |
| 3 | −151 (22.6) | −121 (25.2)‡ | −21 (0.8) | −21 (1.0)‡ | −32 (1.0) | −32 (1.2)‡ | 0.39 (0.01) | 0.42 (0.01)‡* |
| 4 | −184 (24.4) | −155 (26.4)‡ | −23 (0.9) | −23 (1.0)‡ | −34 (1.0) | −34 (1.2)‡ | 0.45 (0.01) | 0.49 (0.01)‡ |
| 5 | −186 (26.5) | −151 (28.0)‡ | −22 (1.0) | −21 (1.2)‡ | −36 (1.1) | −36 (1.3)‡ | 0.52 (0.02) | 0.52 (0.02)‡* |
| 6 | −205 (28.1) | −167 (29.3)‡ | −22 (1.1) | −21 (1.1)‡ | −38 (1.1) | −38 (1.3)‡ | 0.54 (0.02) | 0.58 (0.02)‡* |
| 7 | −220 (30.3) | −172 (31.1)‡ | −22 (1.1) | −21 (1.2)‡ | −39 (1.2) | −39 (1.4)‡ | 0.60 (0.02) | 0.60 (0.02)‡* |
| 8 | −210 (33.2) | −154 (33.5)‡ | −19 (1.3) | −18 (1.3)‡* | −42 (1.4) | −42 (1.5)‡ | 0.61 (0.02) | 0.60 (0.02)‡* |
| 9 | −182 (37.7) | −123 (37.5)‡ | −18 (1.4) | −17 (1.5)‡* | −44 (1.6) | −44 (1.7)‡ | 0.66 (0.03) | 0.65 (0.02)‡* |
| 10 | −219 (43.7) | −155 (42.7)‡ | −19 (1.6) | −18 (1.7)‡* | −43 (1.8) | −44 (1.9)‡ | 0.71 (0.03) | 0.71 (0.03)‡* |
| 0 | 0 | 0 | 0 | |||||
| ART regimen | ||||||||
| 2NRTIs+PI | 219 (46.5) | 144 (36.4)‡ | 4 (2.1) | 2 (1.7) | 5 (2.2) | 3 (1.5)‡ | 0.03 (0.06) | NA |
| 2NRTIs+INSTI | 188 (40.5) | 73 (32.4)‡ | 12 (1.8) | 8 (1.5)‡ | 6 (1.9) | 1 (1.4) | −0.09 (0.05) | NA |
| Others | 185 (43.5) | 38 (33.9) | −2 (2.0) | −3 (1.6)‡ | 4 (2.1) | 3 (1.4)‡ | −0.01 (0.06) | NA |
| 2NRTIs+NNRTI | 0 | |||||||
| Baseline CD8 counts | ||||||||
| 500–999 | 162 (24.5) | 232 (24.0)‡ | 3 (1.3) | 3 (1.1)‡ | −3.0 (1.4) | −1 (1.0) | −0.15 (0.02)‡ | |
| 1000–1499 | 401 (28.5) | 481 (28.5)‡ | 8 (1.6) | 7 (1.3)‡ | −2.9 (1.6) | −1 (1.2) | −0.30 (0.03)‡ | |
| >1500 | 789 (37.2) | 864 (37.9)‡ | 9 (2.0) | 7 (1.8)‡ | −0.8 (2.1) | 0 (1.6) | −0.35 (0.04)‡ | |
| <500 | 0 | 0 | 0 | |||||
| VL <5 0 cps/ml | ||||||||
| No | −78 (12.3) | −31 (15.4)‡ | −8 (0.5) | −0.8 (2.1) | −16 (0.6) | 0 (0.7) | 0.15 (0.01) | −0.075 (0.11) |
| Yes | 0 | 0 | 0 | |||||
Abbreviations: †Est. Coef.: estimated coefficient; SE.: standard error ‡Between group comparisons of the difference of values at particular time points and the baseline value, P-Value < 0.05; *Adjusted multiple comparisons when compared with indicators at 5-year of ART, P-Value < 0.05.